comparemela.com

Latest Breaking News On - European summary - Page 13 : comparemela.com

Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn s disease

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints

Region flamandeUnited kingdomNorthern irelandGreat britainDaniele dambrosioVan gijselSandra cauwenberghsMarieke vermeerschSchwierige zeitenElisa chenaillerGastroenterology department of the university hospital leuvenGroup biomedical sciencesEuropean parliamentGilead sciences incExchange commissionJapanese ministry of health

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn s disease

Investegate announcements from Galapagos NV, Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

Region flamandeUnited kingdomNorthern irelandGreat britainDaniele dambrosioVan gijselSandra cauwenberghsMarieke vermeerschElisa chenaillerGastroenterology department of the university hospital leuvenGroup biomedical sciencesEuropean parliamentGilead sciences incExchange commissionJapanese ministry of healthEuropean union

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

/PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of.

United statesUnited kingdomSan antonioBecker hewesDevelopment of scalableCommunity settingDrug administrationA us analysis using healthAmerican academy of allergyExchange commissionPrnewswire blueprint medicines corporationElectronic health recordConvention centerUs oncology networkMedicines corporationAnnual meeting

Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

/PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company s.

United statesUnited kingdomBecker hewesExchange commissionPrnewswire blueprint medicines corporationDrug administrationMedicines corporationPrescription drug user fee actChief medical officerEuropean summaryProduct characteristicsBlueprint medicinesPrivate securities litigation reform actBlueprint medicineAnnual reportQuarterly report

Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis

95 percent confirmed overall response rate and 37 percent confirmed complete remission rate in treatment-naïve patients with SM-AHN, the most common subtype.

United statesUnited kingdomBecker hewesAmerican society of hematologyExchange commissionPrnewswire blueprint medicines corporationDrug administrationMedicines corporationAmerican societyAnnual meetingDeepti radiaChief medical officerBlueprint medicinesAssessment formEuropean summaryProduct characteristics

vimarsana © 2020. All Rights Reserved.